Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Arcturus Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsArcturus Therapeutics, Inc.

Arcturus Therapeutics, Inc.

ACTIVE

10628 Science Center Dr Ste 250, 加利福尼亚州圣迭戈县, California, United Stateswww.arcturusrx.comSubsidiary$557.6M

Part of Alcobra Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

17

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

11

64.7%

Phase 2

5

29.4%

Phase 3

1

5.9%

Trial Status Distribution

Active, not recruiting

3

17.6%

Completed

8

47.1%

Recruiting

3

17.6%

Terminated

3

17.6%

Clinical Trials

Trials sponsored by this organization (17)

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Dec 202433 participants

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Dec 2024212 participants

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Nov 20249 participants

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Mar 20241,514 participants

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Jan 2024139 participants

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Feb 202339 participants

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Oct 20228 participants

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase Deficiency

Sep 202224 participants

Page 1 of 3

Approvals

No approval data available

News

mRNA Cancer Vaccine Market to Surpass $1.20 Billion in 2026 as Personalized Oncology Gains Momentum

- The global mRNA cancer vaccine market is projected to exceed $1.20 billion in 2026, driven by precision medicine innovations and late-stage clinical validation. - Personalized and off-the-shelf mRNA platforms are gaining traction across multiple tumor types, including high-TMB solid tumors, GI cancers, and breast cancers. - North America leads the market due to advanced infrastructure, while Asia Pacific is expected to register the fastest growth through 2036. - Key players such as Moderna, BioNTech, and Arcturus Therapeutics are shaping the competitive landscape through strategic alliances and manufacturing scale-up.

On this page

Overview
Clinical Trials17
Approvals
News1

Back to Organizations